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Abstract Apoptosis rather than differentiation is a physiological process during myogenesis and muscle regeneration.
When cultured myoblasts were induced to differentiate, we
detected an increase in caspase 8 activity. Pharmacological
inhibition of caspase 8 activity decreased apoptosis. Expression of a dominant-negative mutant of the adapter protein
FADD also abrogated apoptosis, implicating a death ligand pathway. Treatment with TRAIL, but not Fas, induced
apoptosis in these myoblasts. Accordingly, treatment with a
soluble TRAIL decoy receptor or expression of a dominantnegative mutant of the TRAIL receptor DR5 abrogated apoptosis. While TRAIL expression levels remained unaltered
in apoptotic myoblasts, DR5 expression levels increased.
Finally, we also detected a reduction in FLIP, a deathreceptor effector protein and caspase 8 competitive inhibitor, to undetectable levels in apoptotic myoblasts.
Thus, our data demonstrate an important role for the
TRAIL/DR5/FADD/caspase 8 pathway in the apoptosis associated with skeletal myoblast differentiation. Identifying
the functional apoptotic pathways in skeletal myoblasts may
prove useful in minimizing the myoblast apoptosis that contributes pathologically to a variety of diseases and in minimizing the apoptosis of transplanted myoblasts to treat these
and other disease states.
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Introduction
Apoptosis is a common physiological process that occurs in
all tissues and is critical to proper development and homeostasis [1]. In fact, apoptosis and differentiation are often
coordinately regulated with apoptosis serving the critical
function of removing excess or physiologically ineffective
cells [1–3]. Skeletal myoblast apoptosis occurs during myogenesis [2] and muscle regeneration [3] and has been carefully documented in cultures of primary myoblasts [4, 5],
in established myoblast cell lines [6, 7], and in an established muscle satellite cell line [8]. While the coordinate
regulation of differentiation and apoptosis is clearly important under normal physiological conditions, it is likely detrimental to the use of myoblast transfer as a treatment for a
variety of diseases [9, 10]. Further, inappropriate myoblast
apoptosis contributes pathologically to a variety of diseases
[11–13]. Thus, an understanding of the apoptotic process
within skeletal myoblasts may identify targets for therapeutic manipulation relevant to disease states with associated
muscle degeneration and to the use of myoblast transfer as a
therapeutic approach. Further, such information may prove
relevant to the use of apoptotic modifiers to treat a variety of
other pathological conditions [14–18].
While analysis of the apoptotic process that occurs during
the differentiation of skeletal myoblasts is only beginning
[7, 19, 20], the apoptotic process in other systems has
been extensively studied. Mitochondrial permeabilization,
resulting in the release of several pro-apoptotic proteins
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as well as the ensuing dissipation of the mitochondrial
membrane potential, is a critical component of the apoptotic
process in most systems. The molecules directly responsible
for this mitochondrial assault are the pro-apoptotic members
of the Bcl2 family [21–23]. The signaling pathways through
which particular pro-apoptotic Bcl2 family members are
engaged are broadly categorized as either “intrinsic” or
“extrinsic”. The “intrinsic” pathway is initiated through
altered activity of either kinases or transcription factors
while the “extrinsic” pathway is initiated by death ligand
signaling [24]. Several of the proteins released from the
mitochondria play either a direct or indirect role in caspase
activation [22, 23]. Caspases are cysteine-aspartic acid
specific proteases that play a crucial role during apoptosis
[25]. These are categorized as either “initiator” caspases or
“executioner” caspases. Activation of initiator caspase 9 is a
result of the release of cytochrome C from the mitochondria
while activation of initiator caspase 8 is a direct result of
death ligand signaling [24, 26].
Herein, we report a role for caspase 8 activation during the
apoptosis associated with skeletal myoblast differentiation.
This finding prompted an investigation into the role of death
ligand signaling and led us to discover that signaling by the
death ligand TRAIL, through the TRAIL receptor DR5 and
the adapter protein FADD, also plays a role in this apoptotic
process. Further, we report that this death ligand pathway
is engaged through increased expression of the TRAIL receptor DR5 and decreased expression of FLIP, a caspase 8
antagonist.

Materials and methods
Cells and cell culture
The growth and differentiation properties of 23A2 myoblasts
have been reported previously [7, 19]. The 23A2 derivatives expressing dominant negative FADD (23A2:dnFADD
myoblasts) and the 23A2 and C2C12 derivatives expressing dominant negative DR5 (23A2:dnDR5 myoblasts and
C2C12:dnDR5 myoblasts) were generated by transfecting
myoblasts with 300 ng of the pcDNA3:AU1:dnFADD construct or 300 ng of the pcDNA3:AU1:dnDR5 construct using
Lipofectamine Plus (GibcoBRL) as specified by the manufacturer. Briefly, cells were plated at 105 in 100 mm dishes
and transfected the next day with 300 ng of DNA. After
48 h, the culture was passaged and placed in selection media containing G418 (750 µg/ml). After 14 days of drug
selection, individual G418 resistant colonies were isolated
and propagated for further analysis. All cells were maintained on gelatin coated plates in growth medium (GM),
which consists of basal modified Eagle’s medium (BME),
10% fetal bovine serum (FBS), 100 I.U./ml penicillin and
Springer
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100 µg/ml streptomycin (1% P/S). Differentiation was induced by switching cells from GM to differentiation medium
(DM), which consists of BME, 1% P/S and no FBS.

Western blot analysis
Cells were lysed as previously described. The protein concentrations of all lysates were determined using Coomassie
Protein Assay Reagent from Pierce as per manufacturer’s instructions. Following protein determination, lysates (200 µg
for AU1 detection and 100 µg for Bid, FLAG, TRAIL, DR5
and FLIP detection) were denatured in sample buffer (final concentration in lysates of 2% SDS, 10% glycerol, 2%
2-mercaptoethanol, pH 6.8) and electrophoresed through
denaturing polyacrylamide gels (15% for Bid and AU1
detection, 12% for FLIP detection, 10% for FLAG and
TRAIL detection, and 8% for DR5 detection. Following SDS
polyacrylamide gel electrophoresis (SDS-PAGE), samples
were transferred electrophoretically for four amp hours to
Hybond-P polyvinylidene difluoride membranes in transfer
buffer containing 80% methanol and 1 g/L SDS. Membranes
were blocked for one hour in 1 × TBS/0.1% NP40 with 10%
newborn calf serum and 5% dry milk. The following primary
antibodies were incubated with the appropriate membranes at
a dilution of 1:500 overnight: anti-Bid antibody (Santa Cruz),
anti-AU1 antibody (Covance), anti-FLAG (M5, Sigma), antiTRAIL (H-257, Santa Cruz), anti-FLIP (Dave-2, Alexis) and
anti-DR5 (TRAIL-R2, R&D Systems). The actin primary
antibody (Sigma) was used at a dilution of 1:30,000 for
one hour. Appropriate HRP-conjugated secondary antibodies, each diluted 1:1000, were incubated with the membranes
for one hour. After each incubation with antibody and prior
to the addition of chemiluminescent substrate, membranes
were washed five times in 1 × TBS (tris-buffered saline
pH 7.4) with 1% NP-40. Membranes were then incubated
with SuperSignal West Pico Chemiluminescent Substrate
(Pierce) for 60 s and bands were visualized using either
Kodak Scientific Imaging Film or a Bio-Rad Fluor-S Multiimager.

Cytosolic nucleosome ELISA
Myoblasts were plated at equal density and the next day
switched to fresh GM or DM for eight hours. This is the optimal time point for this assay as DNA fragmentation is maximal yet apoptotic myoblasts have not yet detached from the
plate [7]. Cytosolic nucleosomes were measured using the
Cell Death Detection ELISA Plus Kit (Roche Diagnostics)
per manufacturer’s instructions and as previously described
[7] with the following change. Absorbance at 405 nm was
measured at 60 s intervals using a spectrophotometer. Values
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were taken from the time point where all samples were within
the linear range of the assay for each individual experiment
and normalized to cell number from parallel plates.
Caspase 8 assay
Caspase 8 colorimetric assays were performed using the caspase 8 Colorimetric Assay Kit from R&D Systems per manufacturer’s instructions and as previously described [7]. Experiments were performed within the linear range of the assay
and absorbance was normalized to the protein concentration
of each lysate.
Statistics
Statistical analysis was performed using KaleidaGraph data
analysis per the manufacturer’s instructions (version 3.6).
Briefly, for analysis of the data in Fig. 1, a single sample
t-test was used where the test value was the value assigned
to that obtained in GM for (A) and to that obtained with
the solvent control for (B). A paired t-test was use for the
analysis of data in Figs. 2–6.

Results
Inhibition of caspase 8 and FADD signaling abrogates the
apoptosis associated with skeletal myoblast differentiation
We have previously reported a requirement for signaling by
the executioner caspase 3 during the apoptosis associated
with 23A2 myoblast differentiation [7, 19]. To determine if
caspase 8 was an initiator caspase activated during this process, we measured the activation of caspase 8 when skeletal
myoblasts were switched from growth media (GM) to differentiation media (DM). We determined that caspase 8 activity
increases in a time-dependent manner with a 2-fold maximal activation after roughly two hours of culture in DM
(Fig. 1(A)). To determine the significance of caspase 8 activation to the apoptosis of skeletal myoblasts cultured in
DM, myoblasts were cultured in the presence of IETD-fmk,
a selective pharmacological inhibitor of caspase 8. Cytosolic
nucleosomes are the result of DNA fragmentation and nuclear envelope breakdown, hallmarks of the apoptotic process. We have carefully correlated cell density and time in
DM with the level of cytosolic nucleosomes and the percentage of myoblasts undergoing apoptosis [7, 19]. Through this
analysis we determined that, when myoblasts are plated at
a density of 4 × 105 per 100 mm dish, the level cytosolic
nucleosomes present after eight hours of culture in DM is
representative of the 30% of myoblasts that finally undergo
apoptosis [7, 19]. Thus, analysis of cytosolic nucleosomes is

Fig. 1 Caspase 8 activation is required for the apoptosis associated
with skeletal myoblast differentiation. In (A) equal cell numbers were
plated and the next day switched to DM in for the indicated time prior to
the determination of caspase 8 activity. Error bars represent the standard
deviation of the mean from three values from three independent experiments. Each value obtained for caspase 8 activity in DM is significantly
different than that obtained in GM (P < 0.02). In (B) equal cell numbers
were plated and the next day switched to DM in the presence of the indicated concentration of IETD-fmk or solvent for two hours prior to the
assessment of caspase 8 activity or for eight hours prior to the assessment of DNA fragmentation. Caspase 8 activity was measured using
the caspase 8 colorimetric kit (R&D Systems) and DNA fragmentation
was measured using the Cell Death Detection ELISA Plus Kit (Roche
Diagnostics) as described in Materials and Methods. In (B) per cent inhibition was calculated for each sample relative to values obtained from
lysates of cells treated with solvent. Error bars represent the standard
deviation of the mean from three values from three independent experiments. Statistical analysis was performed as described in “Materials
and methods”. Each value obtained after treatment with z-IETD-fmk is
significantly different from the corresponding value obtained after treatment with solvent (P < 0.003). In (C), equal cell numbers were plated
and the next day switched to either fresh GM or DM for 18 h. Apoptotic myoblasts were pelleted from the DM and lysates were prepared
from the apoptotic myoblasts, from the surviving myoblasts cultured
in DM and from the myoblasts cultured in GM. Western analyses, with
actin serving as a protein loading and transfer control, were performed
as described in Materials and Methods. Shown are results from one
experiment that are representative of 2 independent experiments
Springer
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generally performed under these conditions. Treatment with
IETD-fmk provided a dose-dependent inhibition of caspase
8 activity and a corresponding inhibition in the level of cytosolic nucleosomes (Fig. 1(B)).
Since activation of caspase 8 often results in the cleavage of Bid (a BH3-only pro-apoptotic member of the Bcl2
family) to truncated Bid (tBid) [27, 28], we also analyzed
Bid protein status as a consequence of culture in DM. The
apoptotic process associated with differentiation, however,
typically removes only 30% of the myoblasts. This process
is continual and finally complete within 12–18 h of culture
in DM [6, 7]. Further, cell cycle position is implicated in
this process [6, 29, 30] as induction of the cyclin-dependent
kinase (CDK) inhibitor p21(CIP1) [31–34] correlates with
myoblast survival. This protection conferred by p21(CIP1)
requires the retinoblastoma protein [6, 29] suggesting that
this protection is a consequence of the ensuing cell cycle exit.
In an asynchronous population, therefore, only a fraction of
those cells destined to under apoptosis might be expected
to possess altered levels of Bid at any time point. As such,
we had difficulty detecting reproducible changes in the expression level of Bid in a population consisting of both those
myoblasts able to survive (roughly 70% presumably as a consequence of cell cycle exit) and those undergoing apoptosis.
We, therefore, compared Bid protein status in lysates prepared from the apoptotic myoblasts that had detached from
the plate after 18 h of culture in DM, from the corresponding surviving myoblasts cultured in DM and from myoblasts
cultured in GM. We found that the level of full length Bid
detected in myoblasts cultured in GM was similar to that
observed in corresponding surviving myoblasts cultured in
DM, while t-Bid was not detected in either (Fig. 1(C)). In
contrast, only t-Bid was detectable in the apoptotic myoblasts
(Fig. 1(C)).
A role for caspase 8 in the apoptosis associated with differentiation suggested that a death ligand pathway might be
involved. All known death ligand receptors signal through
the adapter protein FADD to induce the activation of caspase
8 [35]. Truncated FADD lacking the death effector domain
(DED) responsible for interaction with the DED of caspase
8 functions as a dominant negative mutant [36]. This mutant
protein has been used successfully to implicate a role for
death ligand signaling [36, 37]. 23A2 myoblasts were transfected with pCDNA3-FADD-DN and G418 resistant clones
were screened for the expression of AU1-tagged FADD-DN
(Fig. 2(A)). The ability of each clone expressing AU1-tagged
FADD-DN to undergo apoptosis as a consequence of culture
in DM was then compared to control 23A2 myoblasts. DNA
fragmentation is induced 3-fold when 23A2 myoblasts are
switched from GM to DM [7, 38] (Fig. 2(B)). The DNA fragmentation detected in each of the FADD-DN clones, however, is below even that detected in control 23A2 myoblasts
cultured in GM (Fig. 2(B)).
Springer
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Fig. 2 Expression of dominant negative FADD abrogates the apoptosis associated with skeletal myoblast differentiation. In (A) equal cell
numbers were plated and the next day lysates were prepared. Western
analyses, with actin serving as a protein loading and transfer control,
were performed as described in Materials and Methods. In (B) equal
cell numbers were plated and the next day switched to either fresh GM
or DM for eight hours prior to the assessment of DNA fragmentation as
described in Fig. 1. Error bars represent mean ± SEM from triplicate
samples. Statistical analysis was performed as described in Materials
and methods. The value obtained for 23A2 myoblasts cultured in DM
is significantly different than the value obtained in GM (P < 0.002)
and the values obtained for each clone cultured in DM are significantly
different than the value obtained for 23A2 myoblasts cultured in DM
(P < 0.003)

TRAIL receptor DR5 signaling plays a role in the apoptosis
associated with skeletal myoblast differentiation
The discovery that expression of FADD-DN blocked the
apoptosis associated with differentiation further implicated
a death ligand pathway in this process. The first death ligand
pathway we investigated was the Fas ligand (FasL)/Fas
pathway. This pathway can be activated either by treatment
with soluble FasL or by treatment with an activating
Fas antibody [39]. Treatment with concentrations of the
activating Fas monoclonal antibody Jo2 (BD-Pharmingen),
sufficient to induce apoptosis in other cell lines [40], did
not induce apoptosis in myoblasts cultured in GM or
increase apoptosis in myoblasts cultured in DM (Fig. 3(A)).
Treatment with soluble FasL, genetically modified to form
active complexes (SUPERFas Ligand, Alexis) also did not
induce or increase apoptosis in 23A2 myoblasts cultured
in either GM or DM, respectively (Fig. 3(B)). Further, full
length FasL presented as membranous vesicles (Upstate)
did not affect apoptosis in myoblasts cultured in either GM
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Fig. 3 Treatment of 23A2 myoblasts with either an activating antiFas antibody or with FasL does not induce apoptosis. In (A) equal cell
numbers were plated and the next day switched to either fresh GM
or DM with the indicated concentration of activating anti-mouse Fas
antibody (clone Jo2, form NA/LE; BD Pharmingen) per manufacturer’s
instructions or control IgG for eight hours prior to the assessment of
DNA fragmentation as described in Fig. 1. In (B) equal cell numbers
were plated and the next day switched to either fresh GM or DM with
the indicated concentration of SUPERFas Ligand for either four or
eight hours prior to the assessment of DNA fragmentation as described
in Fig. 1. In each, error bars represent mean ± SEM from triplicate
samples. Statistical analysis was performed as described in Materials
and methods. Values obtained in the presence of Fas-IgG or FasL are
not significantly different from values obtained in the presence of IgG
control or solvent (P > 0.7 and P > 0.2, respectively)

or DM (data not shown). We next determined if the death
ligand TRAIL could induce apoptosis in skeletal myoblasts.
We found that treatment with recombinant human TRAIL
could induce apoptosis in a dose-dependent (Fig. 4(A)) and
time dependent (Fig. 4(B)) manner in myoblasts cultured
in GM and could increase apoptosis in a dose-dependent
(Fig. 4(A)) and time dependent (Fig. 4(B)) manner in
myoblasts cultured in DM. To determine if endogenous
TRAIL plays a role in the apoptotic process that occurs as a

C
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Fig. 4 Treatment of 23A2 myoblasts with recombinant TRAIL induces apoptosis while a soluble TRAIL decoy receptor inhibits apoptosis. In (A) and (B), equal cell numbers were plated and the next day
switched to either fresh GM or DM with the indicated concentration
of recombinant TRAIL for eight hours in (A), or for the indicated time
in (B), prior to the assessment of DNA fragmentation as described in
Fig. 1. In (C), equal cell numbers were plated and the next day switched
to DM with the indicated concentration of the soluble TRAIL decoy
receptor, TRAILR4:Fc (R&D Systems) for four hours. In each, error
bars represent mean ± SEM from triplicate samples. Statistical analysis was performed as described in Materials and methods. Each value
obtained after treatment with TRAIL is significantly different from the
corresponding value obtained after treatment with solvent (P < 0.03)
and the value obtained in the presence of TRAILR4:Fc is significantly
different from the value obtained after treatment with solvent (P < 0.05)
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Fig. 5 Expression of dominant negative DR5 abrogates the apoptosis 
associated with 23A2 and C2C12 skeletal myoblast differentiation. In
(A) and (C) equal cell numbers were plated and the next day lysates
were prepared. Western analyses, with actin serving as a protein loading
and transfer control, were performed as described in Materials and
Methods. In (B) and (D) equal cell numbers were plated and the next
day switched to either fresh GM or DM, including either solvent or
recombinant TRAIL, for eight hours prior to the assessment of DNA
fragmentation as described in Fig. 1. Error bars represent mean ± SEM
from triplicate samples. Statistical analysis was performed as described
in Materials and methods. The values obtained for each clone cultured in
DM are significantly different than the value obtained for the respective
parental control cells cultured in DM (P < 0.0004 for 23A2 myoblasts
and P < 0.0001 for C2C12 myoblasts). Further, the values obtained for
each clone cultured in DM with TRAIL are significantly different than
the value obtained for the respective parental control cells cultured in
DM with TRAIL (P < 0.0006 for 23A2 myoblasts and P <. 0001 for
C2C12 myoblasts)

consequence of culture in DM, we utilized a soluble human
TRAIL decoy receptor chimera (TRAIL:R4:Fc) which
functions by binding endogenous TRAIL and preventing its
association with the endogenous TRAIL receptor. In support
of a role for endogenous TRAIL in this apoptotic process, the
level of cytosolic nucleosomes in myoblasts cultured in DM
supplemented with the TRAIL:R4:Fc decoy was inhibited
by more than 50% when compared to the level of cytosolic
nucleosomes in myoblasts cultured in DM (Fig. 4(C)).
DR5 is the only TRAIL receptor in murine cells [41].
To further confirm that the TRAIL pathway was actually
responsible for the apoptosis associated with differentiation,
23A2 myoblasts were transfected with pCDNA3-dnDR5
[42] and G418 resistant clones were screened for the expression of FLAG-tagged dnDR5 (Fig. 5(A)). The ability of each
clone expressing FLAG-tagged dnDR5 to undergo apoptosis
as a consequence of culture in DM was then compared to
control 23A2 myoblasts. As before, DNA fragmentation
is induced roughly 3-fold when 23A2 myoblasts are
switched from GM to DM (Figs. 2(B) and 5(B)). The DNA
fragmentation detected in each of the dnDR5 clones is even
less than that routinely observed in myoblasts cultured in
GM (Fig. 5(B)). Further, while treatment with recombinant
TRAIL increased the appearance of cytosolic nucleosomes
roughly two-fold (Figs. 4 and 5(B)) in control 23A2
myoblasts, treatment of the dnDR5 clones with recombinant
TRAIL did not elevate the level of cytosolic nucleosomes
(Fig. 5(B)). To determine if the TRAIL/DR5 pathway
contributed to the apoptosis associated with differentiation
in another established skeletal myoblast cell line, C2C12
myoblasts were transfected with pCDNA3-dnDR5 and
G418 resistant clones were screened for the expression of
FLAG-tagged dnDR5 (Fig. 5(C)). As observed in 23A2 myoblasts, culture in DM results in roughly a 3-fold increase in
the appearance of cytosolic nucleosomes and this is further
elevated when these myoblasts are treated with recombinant
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TRAIL. Further, expression of dnDR5 abrogates both the
apoptosis associated with C2C12 differentiation and the
enhanced apoptosis induced by treatment with recombinant
TRAIL (Fig. 5(D)).
Increased DR5 levels and decreased FLIP levels are
detected in apoptotic myoblasts
We next sought to determine the mechanism through which
the DR5/FADD pathway was engaged during the apoptotic
process associated with skeletal myoblast differentiation.
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Fig. 6 Apoptotic myoblasts possess increased DR5 levels and de- 
creased FLIP levels. Equal cell numbers were plated and the next day
switched to either fresh GM or DM for 18 h. Apoptotic myoblasts were
pelleted from the DM and lysates were prepared from the apoptotic
myoblasts, from the surviving myoblasts cultured in DM and from the
myoblasts cultured in GM. Western analyses, with actin serving as a
protein loading and transfer control, were performed as described in
Materials and Methods. Shown are results from one experiment that
are representative of at least 3 independent experiments for each

In general, signaling through death ligand pathways can be
initiated either through increased expression of the death
ligand or the death receptor or through decreased expression
of a naturally occurring inhibitory protein such as FLIP
(FADD-like IL-1-converting enzyme-inhibitory protein)
[41, 43]. Similar to our analysis of Bid protein levels, we had
difficulty detecting reproducible changes in the expression
levels of these proteins in a population consisting of both
those myoblasts able to survive and those undergoing apoptosis. We, therefore, compared the expression levels of these
proteins in lysates prepared from the apoptotic myoblasts
that had detached from the plate after 18 h of culture in DM,
from the corresponding surviving myoblasts cultured in DM
and from myoblasts cultured in GM. We determined that
the expression level of DR5, but not TRAIL, was elevated
in apoptotic myoblasts when compared to that observed in
corresponding surviving myoblasts cultured in DM or to
myoblasts cultured in GM (Fig. 6(A), (B), (D) and (E)). The
increase in DR5 expression in apoptotic 23A2 myoblasts is
greater than that in apoptotic C2C12 myoblasts when each is
compared to their non-apoptotic counterparts (Fig. 6(B) and
(E)). As a consequence of alternative splicing, two isoforms
of FLIP, FLIPL and FLIPS, can be expressed in other
systems [41, 43]. Although the antibody we used recognizes
an epitope found in both FLIPL and FLIPS , FLIPS is not
detected in our cells under any condition examined. We have
determined, however, that FLIPL is expressed in surviving
23A2 and C2C12 myoblasts, but that both apoptotic 23A2
and C2C12 myoblasts display a reduction in FLIP expression
to levels that are below detection (Fig. 6(C) and (F)).

Discussion
Little has been reported regarding the molecular initiation of
apoptosis in skeletal myoblasts. We have reported a role for
the executioner caspase 3 [7, 19], and others have suggested
a role for caspase 12 and endoplasmic reticulum (ER) stress
signaling through activation of the ATF6 transcription factor
[20]. We, however, do not detect activation of ATF6 (personal observation). Furthermore, ER stress-mediated apoptosis in other systems involves calcium efflux initiated by the
pro-apoptotic Bcl2 family members Bak and Bax. Calcium
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release mediates activation of the protease m-calpain that
cleaves and activates caspase 12 and initates the caspase cascade [44]. We have determined, however, that calpain activity
does not play a role in the apoptotis associated with skeletal myoblast apoptosis (Shaltouki and Weyman, manuscript
in preparation). Herein, we document a role for the initiator caspase 8 and the TRAIL/DR5/FADD pathway in the
apoptosis associated with skeletal myoblast differentiation.
Specifically, this apoptosis is inhibited by pharmacological
abrogation of caspase 8 activity, by expression of a dominant
negative mutant of the death receptor adapter protein FADD,
or by expression of a dominant negative mutant of DR5.
We have further determined that, relative to both proliferating myoblasts cultured in growth media (GM) and surviving, differentiating myoblasts cultured in differentiation
media (DM), those myoblasts induced to undergo apoptosis
in DM possess an increased level of the TRAIL receptor
DR5 and a decreased level of the death-receptor effector
protein and caspase 8 competitive inhibitor FLIP. TRAIL
expression is easily observed and similar levels are detected
in proliferating myoblasts cultured in GM as well as those
myoblasts either undergoing differentiation or apoptosis in
DM. Since soluble TRAIL decoy receptor did inhibit apoptosis, and since skeletal myoblasts are exceptionally migratory
(personal observation), we hypothesize that those myoblasts
with increased levels of DR5 and decreased levels of FLIP
as a consequence of culture in DM are sensitized to undergo
apoptosis when constitutively expressed TRAIL ligand is encountered. Future experiments are focused on determining
the mechanism through which DR5 levels are elevated in
myoblasts undergoing differentiation-associated apoptosis.
DR5 was originally identified as target of the p53 transcription factor and increased expression of DR5 sensitizes cells
to TRAIL mediated apoptosis [45]. DR5 induction by p53
is cell type specific occurring in only spleen, small intestine
and thymus [46]. Consistent with this, p53 plays a role in
the differentiation of skeletal myoblasts but not in the apoptosis of skeletal myoblasts [47] (Freer/Weyman, manuscript
in preparation). Thus, future experiments are focused on
determining the mechanism through which DR5 levels are
elevated in myoblasts undergoing differentiation-associated
apoptosis.
Cells with high levels of FLIP are resistant to apoptosis
while cells with low levels of FLIP are sensitive to apoptosis [41]. An important role for FLIP expression on the
survival of differentiating skeletal myoblasts is suggested
by the finding that skeletal muscle, along with heart, lymphoid tissue and kidney, posess high levels of FLIP protein
[43]. Consistent with this, we have determined that FLIP
levels in myoblasts undergoing apoptosis as a consequence
of culture in DM are reduced to undetectable levels. FLIP
expression levels are regulated by cell cycle position, by the
transcription factor p53, and by the PI3K/Akt/FOXO31 pathSpringer
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way in other systems. Firstly, FLIP levels decrease during
S-phase [48], but the molecular mechanism responsible for
this decrease has not been reported. Since cell cycle proteins
have been implicated in the regulation of the differentiationassociated apoptosis of skeletal myoblasts [6, 30, 49, 50]
the role of cell cycle progression in this process is currently under investigation. Secondly, decreased FLIP levels
can result as a consequence of increased proteolysis mediated by the ubiquitin pathway. This mechanism is employed
during p53-mediated apoptosis [51]. While we, and others
[47] have eliminated a role for p53 in the differentiationassociated apoptosis of skeletal myoblasts, we have not excluded the possibility that decreased levels of FLIP during
this process are a consequence of accelerated degradation.
These experiments are more complicated than employing
pharmacological inhibitors of the proteosome since many
apoptotic molecules involved in TRAIL-induced apoptosis
would be affected [52]. Thirdly, FLIP levels are decreased in
the absence of growth factor mediated signaling through the
PI3K/Akt pathway [53]. Decreased signaling through this
pathway allows nuclear localization of the FOXO3a transcription factor and FLIP levels are repressed by FOXO3a.
Decreased FLIP mRNA levels are associated with Foxo3Amediated repression [54], but the molecular details of this
repression remain to be determined. PI3K/Akt signaling
does play a role in myoblast survival during differentiation
[32] and culture in differentiation media does induce a decrease in PI3K/Akt signaling [55]. However, abrogation of
PI3K/Akt signaling, or constitutively active FOXO3a signaling, for at least 24 h is required to detect decreased levels
of FLIP [54, 56]. We have determined that the decrease in
PI3K/Akt signaling as a consequence of culture in differentiation media is transient, with signaling levels rising again
after 6 h [55]. Further, this same pathway is responsible for
increased expression of TRAIL and the pro-apoptotic Bcl2
family member Bim [57, 58] and the expression level of
neither of these proteins is increased during the apoptosis
associated with differentiation (herein and Freer/Weyman,
manuscript in preparation). DR5 expression is not controlled
by the PI3K/Akt pathway [57]. Taken together, these data do
not suggest that the PI3K/Akt/Foxo3a pathway is responsible for the decreased levels of FLIP detected in myoblasts
undergoing differentiation-associated apoptosis. Thus, future experiments are focused on determining the mechanism
through which FLIP levels are reduced in myoblasts undergoing differentiation-associated apoptosis.
While our studies performed on cultured myoblasts
clearly demonstrate a role for the TRAIL /DR5 /FADD /
caspase 8 pathway in the apoptosis associated with skeletal
myoblast differentiation, no obvious muscle related phenotype has been reported for TRAIL−/− [59], DR5−/− [60],
FADD−/− [61, 62], FLIP−/− [63] or caspase 8−/− mice [64].
In FADD−/− , FLIP−/− or caspase 8−/− mice, this lack of
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muscle phenotype may be attributed to the fact that these
mice are not viable [61–64]. TRAIL−/− and DR5−/− mice,
however, develop normally. A defective apoptotic phenotype
in any cell type in the TRAIL−/− and DR5−/− mice is, however, observed in response to DNA damaging agents such
as chemical carcinogen or ionizing radiation [59, 60]. Thus,
we speculate that lack of a developmental muscle phenotype
could indicate either that this pathway has no role during
developmental myogenesis or that compensatory signaling
negates detection of such a role. Further, a reduced apoptotic phenotype in either TRAIL−/− and DR5−/− skeletal
myoblasts might only be observed in response to specific
stimuli such as conditions that lead to muscle wasting or
regeneration, or in the context of myoblast transplantation
[1–3, 9, 10, 12, 13, 65–71]. These future studies, combined
with further analysis to understand the molecular mechanisms mediating the increased level of the TRAIL receptor
DR5 and the decreased level of FLIP in apoptotic myoblasts,
might identify additional therapeutic targets for manipulation to modify skeletal myoblast apoptosis relevant to the
amelioration of disease states with associated muscle degeneration as well as to the use of myoblast transfer as a
therapeutic approach.

Conclusion
Inhibition of TRAIL, DR5, FADD or caspase 8 signaling
inhibits the apoptosis associated with skeletal myoblast differentiation. Myoblasts undergoing apoptosis rather than differentiation possess increased levels of the TRAIL receptor
DR5 and decreased levels of the caspase 8 antagonist FLIP.
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